8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 16, 2026·SEC
Cerus Corporation(CERS)Earnings, Financials & Key Ratios
CERS•NASDAQ
Price updated Jun 19, 2026
AboutCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.Show more
- Revenue$206M+14.3%
- EBITDA-$34M-177.7%
- Net Income-$16M+25.3%
- EPS (Diluted)-0.08+25.5%
- Gross Margin53.5%-3.1%
- EBITDA Margin-16.66%-142.8%
- Operating Margin-17.63%-123.5%
- Net Margin-7.58%+34.7%
- ROE-25.65%+32.4%
CERS Key Insights
Cerus Corporation (CERS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 23.6%
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓Strong 5Y sales CAGR of 17.5%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CERS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CERS Price & Volume
Cerus Corporation (CERS) stock price & volume — 10-year historical chart
Loading chart...
CERS Growth Metrics
Cerus Corporation (CERS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.67%
5 Years17.53%
3 Years8.35%
TTM16.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM49.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.61%
Return on Capital
10 Years-42.06%
5 Years-24.31%
3 Years-21.59%
Last Year-28.14%
CERS Recent Earnings
Cerus Corporation (CERS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.01+66.7%
$0.03
Rev
$60M+7.6%
$56M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.01+0.0%
$0.01
Rev
$65M+4.5%
$62M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.00+99.5%
$0.02
Rev
$53M-11.1%
$59M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.03-50.0%
$0.02
Rev
$52M-3.4%
$54M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.01vs $0.03+66.7% | $60Mvs $56M+7.6% |
| Q2 2026 | Mar 2, 2026 | $0.01vs $0.01+0.0% | $65Mvs $62M+4.5% |
| Q4 2025 | Nov 6, 2025 | $0.00vs $0.02+99.5% | $53Mvs $59M-11.1% |
| Q3 2025 | Aug 5, 2025 | $0.03vs $0.02-50.0% | $52Mvs $54M-3.4% |
Based on last 12 quarters of dataView full earnings history →
CERS Peer Comparison
Cerus Corporation (CERS) competitors in Renal, dialysis, and blood purification — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TXG | 4.41B | 34.76 | -99.30 | 5.25% | -3.55% | -2.86% | 0.20 | |
 BLFS | 1.27B | 26.04 | -104.16 | 16.97% | -10.52% | -2.91% | 0.05 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 HAE | 3.45B | 74.17 | 36.18 | -1.97% | 7.29% | 11.32% | 1.54 | |
 TER | 68.56B | 437.92 | 125.84 | 13.13% | 22.55% | 29.72% | 0.12 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 |
Compare CERS vs Peers
Cerus Corporation (CERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CERS Income Statement
Cerus Corporation (CERS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 43.57M | 60.91M | 74.65M | 91.92M | 130.86M | 162.05M | 156.37M | 180.27M | 206.13M | 216.56M |
Revenue Growth % | 17.17% | 39.8% | 22.56% | 23.14% | 42.36% | 23.83% | -3.51% | 15.29% | 14.35% | 16.97% |
Cost of Goods Sold | 22.53M | 31.63M | 33.42M | 41.16M | 63.48M | 74.95M | 69.97M | 80.75M | 95.84M | 101.8M |
COGS % of Revenue | 51.71% | 51.94% | 44.77% | 44.77% | 48.51% | 46.25% | 44.75% | 44.79% | 46.5% | - |
Gross Profit | 21.04M▲ 0% | 29.27M▲ 39.2% | 41.23M▲ 40.8% | 50.76M▲ 23.1% | 67.38M▲ 32.7% | 87.09M▲ 29.3% | 86.4M▼ 0.8% | 99.52M▲ 15.2% | 110.29M▲ 10.8% | 114.76M▲ 0% |
Gross Margin % | 48.29% | 48.06% | 55.23% | 55.23% | 51.49% | 53.75% | 55.25% | 55.21% | 53.5% | 52.99% |
Gross Profit Growth % | 24.57% | 39.15% | 40.84% | 23.12% | 32.74% | 29.25% | -0.8% | 15.19% | 10.82% | - |
Operating Expenses | 78.57M | 84.26M | 107.46M | 109.1M | 116.32M | 121.17M | 116.45M | 113.75M | 146.63M | 138.68M |
OpEx % of Revenue | 180.33% | 138.34% | 143.95% | 118.69% | 88.89% | 74.78% | 74.47% | 63.1% | 71.14% | - |
Selling, General & Admin | 52.41M | 56.84M | 66.2M | 67.02M | 81.29M | 83.33M | 75.52M | 75.89M | 80.91M | 80.58M |
SG&A % of Revenue | 120.3% | 93.32% | 88.69% | 72.91% | 62.12% | 51.43% | 48.29% | 42.1% | 39.25% | - |
Research & Development | 33.71M | 42.56M | 60.38M | 64.41M | 63.69M | 64.11M | 67.64M | 58.91M | 65.72M | 65.65M |
R&D % of Revenue | 77.37% | 69.88% | 80.88% | 70.07% | 48.67% | 39.56% | 43.26% | 32.68% | 31.88% | - |
Other Operating Expenses | 3.86M | 1.75M | -19.13M | -22.33M | -28.66M | -26.27M | -26.7M | -21.05M | 0 | -1000K |
Operating Income | -57.53M▲ 0% | -54.99M▲ 4.4% | -66.23M▼ 20.4% | -58.33M▲ 11.9% | -48.94M▲ 16.1% | -34.08M▲ 30.4% | -30.05M▲ 11.8% | -14.22M▲ 52.7% | -36.35M▼ 155.5% | -17.69M▲ 0% |
Operating Margin % | -132.05% | -90.28% | -88.72% | -63.46% | -37.4% | -21.03% | -19.22% | -7.89% | -17.63% | -8.17% |
Operating Income Growth % | 6.37% | 4.42% | -20.44% | 11.92% | 16.11% | 30.36% | 11.82% | 52.67% | -155.51% | - |
EBITDA | -55.72M | -53.54M | -63.82M | -53.88M | -45.79M | -31.1M | -27.45M | -12.37M | -34.35M | -15.86M |
EBITDA Margin % | -127.89% | -87.91% | -85.5% | -58.61% | -34.99% | -19.19% | -17.56% | -6.86% | -16.66% | -7.32% |
EBITDA Growth % | 6.56% | 3.91% | -19.2% | 15.58% | 15.02% | 32.08% | 11.71% | 54.94% | -177.66% | 1.99% |
D&A (Non-Cash Add-back) | 1.81M | 1.45M | 2.4M | 4.46M | 3.15M | 2.98M | 2.6M | 1.85M | 2M | 1.83M |
EBIT | -53.68M | -53.33M | -67.02M | -55.83M | -49.13M | -36.51M | -28.94M | -11.88M | -36.35M | -16.39M |
Net Interest Income | -3.02M | -4.01M | -6.07M | -3.75M | -4.92M | -5.83M | -8.39M | -8.88M | -8.34M | -6.23M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 3.02M | 4.01M | 6.07M | 3.75M | 4.92M | 5.83M | 8.39M | 8.88M | 8.34M | 6.23M |
Other Income/Expense | 832K | -2.35M | -4.75M | -1.24M | -5.12M | -8.26M | -7.27M | -6.53M | 21.06M | 8.5M |
Pretax Income | -56.7M▲ 0% | -57.34M▼ 1.1% | -70.98M▼ 23.8% | -59.57M▲ 16.1% | -54.06M▲ 9.3% | -42.34M▲ 21.7% | -37.32M▲ 11.8% | -20.76M▲ 44.4% | -15.28M▲ 26.4% | -9.2M▲ 0% |
Pretax Margin % | -130.14% | -94.13% | -95.09% | -64.81% | -41.31% | -26.13% | -23.87% | -11.51% | -7.41% | -4.25% |
Income Tax | 3.89M | 229K | 263K | 284K | 319K | 488K | 325K | 205K | 354K | 371K |
Effective Tax Rate % | -6.86% | -0.4% | -0.37% | -0.48% | -0.59% | -1.15% | -0.87% | -0.99% | -2.32% | -4.03% |
Net Income | -60.59M▲ 0% | -57.56M▲ 5.0% | -71.24M▼ 23.8% | -59.86M▲ 16.0% | -54.37M▲ 9.2% | -42.78M▲ 21.3% | -37.49M▲ 12.4% | -20.92M▲ 44.2% | -15.63M▲ 25.3% | -9.55M▲ 0% |
Net Margin % | -139.06% | -94.51% | -95.44% | -65.12% | -41.55% | -26.4% | -23.97% | -11.6% | -7.58% | -4.41% |
Net Income Growth % | 3.69% | 4.99% | -23.76% | 15.98% | 9.16% | 21.32% | 12.37% | 44.2% | 25.29% | 49.6% |
Net Income (Continuing) | -60.59M | -57.56M | -71.24M | -59.86M | -54.38M | -42.83M | -37.65M | -20.96M | -15.64M | -9.56M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 998K | 952K | 794K | 751K | 741K | 733K |
EPS (Diluted) | -0.56▲ 0% | -0.44▲ 21.4% | -0.51▼ 15.9% | -0.37▲ 27.5% | -0.32▲ 13.5% | -0.24▲ 25.0% | -0.21▲ 12.5% | -0.11▲ 47.6% | -0.08▲ 25.5% | -0.05▲ 0% |
EPS Growth % | 9.68% | 21.43% | -15.91% | 27.45% | 13.51% | 25% | 12.5% | 47.62% | 25.45% | 49.61% |
EPS (Basic) | -0.56 | -0.44 | -0.51 | -0.37 | -0.32 | -0.24 | -0.21 | -0.11 | -0.08 | - |
Diluted Shares Outstanding | 108.22M | 131.66M | 139.83M | 163.95M | 171.28M | 176.54M | 180.27M | 184.56M | 190.59M | 194.14M |
Basic Shares Outstanding | 108.19M | 130.83M | 139.83M | 163.95M | 171.28M | 176.54M | 180.27M | 184.56M | 190.59M | 194.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CERS Balance Sheet
Cerus Corporation (CERS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 89.9M | 146.9M | 128.11M | 183.43M | 187.1M | 170.14M | 144.44M | 152.02M | 174.38M | 175.34M |
Cash & Short-Term Investments | 60.7M | 117.58M | 85.72M | 133.59M | 129.36M | 102.15M | 65.85M | 80.45M | 82.88M | 80.42M |
Cash Only | 13.68M | 28.86M | 34.99M | 36.59M | 48.76M | 35.59M | 11.65M | 20.27M | 19.96M | 27.85M |
Short-Term Investments | 47.01M | 88.72M | 50.73M | 97M | 80.6M | 66.57M | 54.2M | 60.19M | 62.92M | 52.58M |
Accounts Receivable | 12.41M | 8.75M | 16.88M | 21.17M | 25.13M | 34.43M | 35.5M | 29.78M | 30.37M | 29.32M |
Days Sales Outstanding | 104.01 | 52.45 | 82.55 | 84.05 | 70.09 | 77.54 | 82.87 | 60.29 | 53.78 | 50.93 |
Inventory | 14.46M | 13.54M | 19.49M | 23.25M | 26.79M | 29M | 39.87M | 38.15M | 56.1M | 61.12M |
Days Inventory Outstanding | 234.2 | 156.22 | 212.87 | 206.23 | 154.07 | 141.23 | 207.98 | 172.45 | 213.65 | 201.59 |
Other Current Assets | 2.33M | 0 | 0 | 0 | 0 | 4.56M | 3.22M | 3.64M | 5.03M | 4.47M |
Total Non-Current Assets | 8.35M | 16.56M | 37.43M | 37.98M | 50.4M | 47.95M | 53.31M | 48.9M | 47.48M | 47.57M |
Property, Plant & Equipment | 2.12M | 8.13M | 29.02M | 26.99M | 25.18M | 23.48M | 19.35M | 15.54M | 19.33M | 18.7M |
Fixed Asset Turnover | 20.56x | 7.49x | 2.57x | 3.41x | 5.20x | 6.90x | 8.08x | 11.60x | 10.66x | 12.69x |
Goodwill | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M |
Intangible Assets | 536K | 334K | 132K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 247K | 2.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.14M |
Other Non-Current Assets | 4.38M | 6.78M | 6.96M | 9.68M | 23.9M | 23.15M | 32.64M | 32.04M | 26.83M | 27.55M |
Total Assets | 98.24M▲ 0% | 163.46M▲ 66.4% | 165.53M▲ 1.3% | 221.41M▲ 33.8% | 237.5M▲ 7.3% | 218.09M▼ 8.2% | 197.75M▼ 9.3% | 200.92M▲ 1.6% | 221.86M▲ 10.4% | 222.91M▲ 0% |
Asset Turnover | 0.44x | 0.37x | 0.45x | 0.42x | 0.55x | 0.74x | 0.79x | 0.90x | 0.93x | 0.99x |
Asset Growth % | -5.06% | 66.38% | 1.27% | 33.76% | 7.26% | -8.17% | -9.33% | 1.6% | 10.42% | 46.62% |
Total Current Liabilities | 23.13M | 52.68M | 50.34M | 59.97M | 78.56M | 117.06M | 67.52M | 63.61M | 100.8M | 107.38M |
Accounts Payable | 10.97M | 18.59M | 22.18M | 24.21M | 35.61M | 33M | 23.84M | 21.7M | 28.01M | 0 |
Days Payables Outstanding | 177.78 | 214.55 | 242.3 | 214.73 | 204.76 | 160.71 | 124.38 | 98.07 | 106.66 | 75.29 |
Short-Term Debt | 0 | 7.86M | 5.02M | 8.52M | 14.7M | 56.16M | 20M | 19.3M | 46.25M | 55.54M |
Deferred Revenue (Current) | 445K | 498K | 570K | 577K | 673K | 589K | 2M | 1.4M | 1.27M | 7.49M |
Other Current Liabilities | 4.34M | 14.96M | 12.7M | 16M | 18.51M | 17.58M | 11.82M | 11.94M | 25.27M | 50.12M |
Current Ratio | 3.89x | 2.79x | 2.55x | 3.06x | 2.38x | 1.45x | 2.14x | 2.39x | 1.73x | 1.63x |
Quick Ratio | 3.26x | 2.53x | 2.16x | 2.67x | 2.04x | 1.21x | 1.55x | 1.79x | 1.17x | 1.06x |
Cash Conversion Cycle | 160.43 | -5.89 | 53.11 | 75.54 | 19.4 | 58.07 | 166.47 | 134.67 | 160.77 | 177.23 |
Total Non-Current Liabilities | 36.17M | 26.26M | 58.15M | 57.63M | 73.33M | 32.47M | 76.78M | 80.41M | 56.09M | 47.24M |
Long-Term Debt | 29.8M | 22.01M | 39.41M | 39.59M | 54.72M | 13.64M | 59.8M | 64.86M | 40.55M | 9.38M |
Capital Lease Obligations | 0 | 0 | 18.41M | 16.87M | 16.26M | 15.33M | 13.75M | 11.66M | 10.15M | 32.23M |
Deferred Tax Liabilities | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6.38M | 4.25M | 327K | 1.17M | 2.34M | 3.5M | 3.24M | 3.89M | 5.39M | 37.86M |
Total Liabilities | 59.3M | 78.94M | 108.48M | 117.61M | 151.88M | 149.53M | 144.3M | 144.02M | 156.89M | 154.62M |
Total Debt | 29.8M | 29.87M | 64.45M | 66.89M | 87.59M | 87.24M | 96M | 98.1M | 96.95M | 64.92M |
Net Debt | 16.11M | 1.01M | 29.46M | 30.3M | 38.83M | 51.65M | 84.35M | 77.83M | 76.98M | 37.07M |
Debt / Equity | 0.77x | 0.35x | 1.13x | 0.64x | 1.02x | 1.27x | 1.80x | 1.72x | 1.49x | 0.95x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.09x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.34x |
Interest Coverage | -17.76x | -13.31x | -11.05x | -14.90x | -9.98x | -6.26x | -3.45x | -1.34x | -4.36x | -2.63x |
Total Equity | 38.94M▲ 0% | 84.52M▲ 117.0% | 57.05M▼ 32.5% | 103.81M▲ 81.9% | 85.62M▼ 17.5% | 68.56M▼ 19.9% | 53.44M▼ 22.1% | 56.9M▲ 6.5% | 64.97M▲ 14.2% | 68.29M▲ 0% |
Equity Growth % | -32.61% | 117.05% | -32.5% | 81.95% | -17.52% | -19.92% | -22.05% | 6.46% | 14.18% | 61.86% |
Book Value per Share | 0.36 | 0.64 | 0.41 | 0.63 | 0.50 | 0.39 | 0.30 | 0.31 | 0.34 | 0.35 |
Total Shareholders' Equity | 38.94M | 84.52M | 57.05M | 103.81M | 84.62M | 67.61M | 52.65M | 56.15M | 64.22M | 68.29M |
Common Stock | 115K | 136K | 144K | 168K | 174K | 177K | 181K | 186K | 192K | 200K |
Retained Earnings | -721.3M | -778.87M | -850.11M | -909.97M | -964.34M | -1.01B | -1.04B | -1.07B | -1.08B | -1.08B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -97K | -281K | 114K | 674K | -149K | -2.79M | -1.27M | -400K | -156K | -323K |
Minority Interest | 0 | 0 | 0 | 0 | 998K | 952K | 794K | 751K | 741K | 733K |
CERS Cash Flow Statement
Cerus Corporation (CERS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -52.23M | -31.25M | -65.5M | -41.81M | -33.92M | -25.61M | -43.17M | 11.36M | 11.36M | 2.63M |
Operating CF Margin % | -119.89% | -51.3% | -87.74% | -45.49% | -25.92% | -15.81% | -27.61% | 6.3% | 5.51% | - |
Operating CF Growth % | 2.42% | 40.18% | -109.62% | 36.17% | 18.87% | 24.49% | -68.53% | 126.31% | 0% | -998.1% |
Net Income | -60.59M | -57.56M | -71.24M | -59.86M | -54.38M | -42.83M | -37.49M | -20.96M | -15.63M | -9.55M |
Depreciation & Amortization | 1.81M | 1.45M | 2.4M | 3.11M | 3.15M | 2.98M | 2.6M | 1.85M | 1.85M | 2M |
Stock-Based Compensation | 9.36M | 10.39M | 13.31M | 18.03M | 23.57M | 24.46M | 20.27M | 22.87M | 22.87M | 21.14M |
Deferred Taxes | 3.71M | 4K | 0 | 0 | 462K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -2.92M | 1.25M | 2.33M | 1.11M | 2.67M | 5.82M | 3.49M | 2.37M | 9.09M | 1.76M |
Working Capital Changes | -3.61M | 13.22M | -12.3M | -4.2M | -9.4M | -16.05M | -32.03M | 5.23M | -6.83M | -12.7M |
Change in Receivables | -5.55M | 3.66M | -8.07M | -4.13M | -4.21M | -9.2M | -1.1M | 5.5M | -396K | -3.19M |
Change in Inventory | -2.09M | 806K | -6.04M | -4.03M | -19.61M | -1.77M | -14.95M | 7.03M | -14.68M | -14.16M |
Change in Payables | 2.49M | 5.68M | 4.94M | 1.98M | 12.2M | -4.91M | -7.33M | -1.48M | 5.72M | 4.83M |
Cash from Investing | 421K | -43.85M | 28.18M | -49.56M | 12.69M | 8.46M | 8.62M | -8.13M | -8.13M | 4.88M |
Capital Expenditures | -353K | -1.14M | -8.94M | -1.61M | -910K | -2M | -4.6M | -2.84M | -2.84M | -2.96M |
CapEx % of Revenue | 0.81% | 1.88% | 11.97% | 1.76% | 0.7% | 1.23% | 2.94% | 1.57% | 1.38% | 1.37% |
Acquisitions | -3.47M | 0 | 0 | 0 | 910K | -10.46M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 3.47M | -42.7M | 0 | 0 | -910K | 10.46M | 0 | 0 | 0 | 1.97M |
Cash from Financing | 43M | 92.75M | 43.49M | 91.78M | 34.29M | 4.19M | 10.67M | 4.96M | 4.96M | 352K |
Debt Issued (Net) | 10.38M | -133K | 13.35M | 3.5M | 21.18M | 212K | 9.92M | 4.3M | -329K | 128K |
Equity Issued (Net) | 30.2M | 85.04M | 26.93M | 76.53M | 2.74M | -104K | -175K | 0 | 560K | 263K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -104K | -175K | 0 | 0 | 263K |
Other Financing | 2.43M | 7.85M | 3.21M | 11.75M | 10.37M | 4.08M | 925K | 667K | 4.73M | -39K |
Net Change in Cash | -8.81M▲ 0% | 17.66M▲ 300.3% | 5.83M▼ 67.0% | 1.48M▼ 74.6% | 12.14M▲ 719.2% | -13.69M▼ 212.7% | -24M▼ 75.4% | 8M▲ 133.3% | 8M▲ 0.0% | 8.4M▲ 0% |
Free Cash Flow | -52.59M▲ 0% | -32.39M▲ 38.4% | -74.43M▼ 129.8% | -43.43M▲ 41.7% | -34.83M▲ 19.8% | -27.61M▲ 20.7% | -47.77M▼ 73.0% | 8.52M▲ 117.8% | 8.52M▲ 0.0% | -1.22M▲ 0% |
FCF Margin % | -120.7% | -53.18% | -99.71% | -47.24% | -26.62% | -17.04% | -30.55% | 4.73% | 4.13% | -0.56% |
FCF Growth % | 2.78% | 38.41% | -129.81% | 41.66% | 19.79% | 20.72% | -72.97% | 117.84% | 0% | -118.16% |
FCF per Share | -0.49 | -0.25 | -0.53 | -0.26 | -0.20 | -0.16 | -0.26 | 0.05 | 0.04 | -0.01 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.54x | 0.92x | 0.70x | 0.62x | 0.60x | 1.15x | -0.54x | -0.73x | 0.13x |
Interest Paid | 2.03M | 2.73M | 3.08M | 3.27M | 4.18M | 5.1M | 9.21M | 0 | 0 | 0 |
Taxes Paid | 160K | 254K | 229K | 265K | 278K | 270K | 322K | 356K | 0 | 0 |
CERS Key Ratios
Cerus Corporation (CERS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -125.27% | -93.25% | -100.65% | -74.42% | -57.41% | -55.49% | -61.45% | -37.92% | -25.65% | -15.18% |
Return on Invested Capital (ROIC) | -78.7% | -58.67% | -57.74% | -39.66% | -28.39% | -20.9% | -17.47% | -7.83% | -19.7% | -9.99% |
Gross Margin | 48.29% | 48.06% | 55.23% | 55.23% | 51.49% | 53.75% | 55.25% | 55.21% | 53.5% | 52.99% |
Net Margin | -139.06% | -94.51% | -95.44% | -65.12% | -41.55% | -26.4% | -23.97% | -11.6% | -7.58% | -4.41% |
Debt / Equity | 0.77x | 0.35x | 1.13x | 0.64x | 1.02x | 1.27x | 1.80x | 1.72x | 1.49x | 0.95x |
Interest Coverage | -17.76x | -13.31x | -11.05x | -14.90x | -9.98x | -6.26x | -3.45x | -1.34x | -4.36x | -2.63x |
FCF Conversion | 0.86x | 0.54x | 0.92x | 0.70x | 0.62x | 0.60x | 1.15x | -0.54x | -0.73x | 0.13x |
Revenue Growth | 17.17% | 39.8% | 22.56% | 23.14% | 42.36% | 23.83% | -3.51% | 15.29% | 14.35% | 16.97% |
Related:CERS Dividend History·CERS Revenue History·CERS Price History·CERS P/E History·CERS Financial Ratios·CERS Institutional Holders
CERS SEC Filings & Documents
Cerus Corporation (CERS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CERS Frequently Asked Questions
Cerus Corporation (CERS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cerus Corporation (CERS) reported $216.6M in revenue for fiscal year 2025. This represents a 3038% increase from $6.9M in 1997.
Cerus Corporation (CERS) grew revenue by 14.3% over the past year. This is steady growth.
Cerus Corporation (CERS) reported a net loss of $9.6M for fiscal year 2025.
Dividend & Returns
Cerus Corporation (CERS) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.
Cerus Corporation (CERS) had negative free cash flow of $1.2M in fiscal year 2025, likely due to heavy capital investments.